Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes mellitus

Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS

Nature Reviews Nephrology volume 13, pages 517–518 (2017)Cite this article

Subjects

Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program is the second major trial to demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system in patients with type 2 diabetes mellitus.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanisms of renal and cardiovascular protection by SGLT2 inhibition.

References

  1. Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M. & Parikh, C. R. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch. Intern. Med. 172, 761–769 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

    Article  CAS  PubMed  Google Scholar 

  3. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1611925 (2017).

  5. Khunti, K. et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38, 316–322 (2015).

    Article  PubMed  Google Scholar 

  6. Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39, 1108–1114 (2016).

    Article  PubMed  Google Scholar 

  7. Mudaliar, S., Alloju, S. & Henry, R. R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis. Diabetes Care 39, 1115–1122 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Vallon, V. & Thomson, S. C. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74, 351–375 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Vallon, V. & Thomson, S. C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215–225 (2017).

    Article  CAS  PubMed  Google Scholar 

  10. O'Bryan, G. T. & Hostetter, T. H. The renal hemodynamic basis of diabetic nephropathy. Semin. Nephrol. 17, 93–100 (1997).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Volker Vallon and Scott C. Thomson are at the Division of Nephrology & Hypertension, Departments of Medicine and Pharmacology, University of California San Diego & VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, California 92161, USA.,

    Volker Vallon & Scott C. Thomson

Authors
  1. Volker Vallon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott C. Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Volker Vallon.

Ethics declarations

Competing interests

Over the past 36 months, V.V. has served as a consultant and received honoraria from Bayer, Boehringer Ingelheim, Intarcia Therapeutics, Astra-Zeneca, Janssen Pharmaceutical, Eli Lilly and Merck, and received grant support for investigator-initiated research from Astra-Zeneca, Bayer, Boehringer Ingelheim, Fresenius, and Janssen. Over the past 36 months, S.C.T. has received research support from Merck and Pfizer. These companies were not involved in the development or writing of this commentary.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vallon, V., Thomson, S. Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. Nat Rev Nephrol 13, 517–518 (2017). https://doi.org/10.1038/nrneph.2017.113

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2017.113

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing